1. Home
  2. OTLY vs PRTC Comparison

OTLY vs PRTC Comparison

Compare OTLY & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oatly Group AB

OTLY

Oatly Group AB

N/A

Current Price

$9.91

Market Cap

394.1M

ML Signal

N/A

Logo PureTech Health plc

PRTC

PureTech Health plc

N/A

Current Price

$15.78

Market Cap

464.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OTLY
PRTC
Founded
1994
2015
Country
Sweden
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
394.1M
464.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
OTLY
PRTC
Price
$9.91
$15.78
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$15.50
N/A
AVG Volume (30 Days)
49.4K
4.1K
Earning Date
04-29-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.91
N/A
Revenue Next Year
$5.50
N/A
P/E Ratio
N/A
$8.09
Revenue Growth
N/A
N/A
52 Week Low
$8.35
$13.30
52 Week High
$18.84
$20.00

Technical Indicators

Market Signals
Indicator
OTLY
PRTC
Relative Strength Index (RSI) 37.54 35.89
Support Level N/A $15.60
Resistance Level $12.58 $18.10
Average True Range (ATR) 0.53 0.47
MACD -0.10 -0.11
Stochastic Oscillator 10.74 3.48

Price Performance

Historical Comparison
OTLY
PRTC

About OTLY Oatly Group AB

Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: